TG Therapeutics Announces Data Presentations at


NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the schedule for the next data presentations at the 16e International Malignant Lymphoma Congress (ICML), to be held virtually June 18-22, 2021. Details of the data presentations are included below.

Title of the poster presentation: TG-1701, a selective bruton tyrosine kinase (BTK) inhibitor, as monotherapy and in combination with oblituximab and umbralisib (U2) in patients with malignant B-cell tumors

  • Abstract Book Number: 236
  • Presentation available on request: Friday, June 18, 2021 at 9:00 a.m. CEST
  • Principal author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Hematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia

Title of the poster presentation: Antitumor activity of novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling and improvement of anti-CD20 therapy in non-Hodgkin B-cell lymphoma

  • Abstract Book Number: 241
  • Presentation available on request: Friday, June 18, 2021 at 9:00 a.m. CEST
  • Main author: Gaël Roué, PhD, head of the Lymphoma Translational Group, Josep Carreras Leukemia Research Institute (IJC)

The above summaries are now available in the 16e ICML Book of Abstracts, published online at Additional information is available on the ICML meeting website at

At the time of each presentation, the data presented will be available on the Publications page, located in the Pipeline section, of the Company’s website at

TG Therapeutics is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for malignant B cell tumors and autoimmune diseases. In addition to an active research pipeline comprising five investigational drugs in these therapeutic areas, TG has received US FDA expedited approval for UKONIQ® (umbralisib), for the treatment of adult patients with relapsed / refractory marginal zone lymphoma who have received at least one prior anti-CD20 therapy and relapsed / refractory follicular lymphoma who have received at least three prior lines of systemic therapy. Currently, the Company has two phase 3 programs in development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational drugs in phase 1 clinical development. For more information, visit and follow us on Twitter @TGTherapeutics and Linkedin.

UKONIQ® is a trademark of TG Therapeutics, Inc.

This press release contains forward-looking statements that involve a number of risks and uncertainties. For such statements, we claim safe harbor protection for forward-looking statements contained in the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements regarding expectations and plans. clinical trials evaluating TG-1701 as monotherapy and in combination with UKONIQ® (umbralisib) and ublituximab (U2), the availability of results from these trials and the potential of TG-1701 as a treatment for CLL.

In addition to the risk factors identified from time to time in our reports filed with the United States Securities and Exchange Commission, factors that could cause our actual results to differ materially are as follows: test results, including clinical studies evaluating TG-1701 in combination with U2 will not be reproduced in the final data sets or in future studies; the risk that the safety profile observed with TG-1701 as monotherapy and in combination with U2 may change as additional patients are exposed for longer periods of time; the risk that TG-1701 as monotherapy or in combination with U2 may not be safe and effective; uncertainties inherent in research and development; the risk that the ongoing COVID-19 pandemic and associated government control measures negatively impact our research and development plans or commercialization efforts; and the risk that preclinical results will not be validated in clinical trials. Further discussion of these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in our other filings with the U.S. Securities and Exchange Commission. United.

All forward-looking statements made in this press release speak only as of the date of this press release. We do not undertake to update these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and previous releases are available at Information found on our website is not incorporated by reference in this press release and is included for reference purposes only.


Investor Relations
Email: [email protected]
Telephone: 1.877.575.TGTX (8489), option 4

Media Relations:
Email: [email protected]
Telephone: 1.877.575.TGTX (8489), option 6


About Author

Comments are closed.